Funding

Voyager Therapeutics/Michael J. Fox Foundation

Title: “A Phase I Bridging Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV2-hAADC) Administered by MRI-Guided Real-Time Convective Infusion in the Putamen of Subjects with Parkinson’s Disease" 

Voyager Therapeutics

Title: “An Open-label Safety and Efficacy Study of AAV2-hAADC Administered by MRI-Guided Convective Infusion using a Posterior Trajectory into the Putamen of Participants with Parkinson’s Disease with Fluctuating Responses to Levodopa”

Neurocrine Biosciences/Voyager Therapeutics

Title: “A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson’s Disease with Motor Fluctuations”

Brain Neurotherapy Bio

Title: "Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Parkinson’s Disease”

uniQure

Title: “A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington Disease”